Advertisement

Pharmaceutical Research

, Volume 18, Issue 5, pp 694–701 | Cite as

Lipophilicity Behaviour of the Zwitterionic Antihistamine Cetirizine in Phosphatidylcholine Liposomes/Water Systems

  • Georgette Plemper van Balen
  • Giulia Caron
  • Giuseppe Ermondi
  • Alessandra Pagliara
  • Teresa Grandi
  • Géraldine Bouchard
  • Roberta Fruttero
  • Pierre–Alain Carrupt
  • Bernard Testa
Article

Abstract

Purpose. The partitioning of cetirizine in a phosphatidylcholine liposomes/water system was compared with that of hydroxyzine and acrivastine to gain insight into the mechanisms of interaction of its various electrical species with membranes.

Methods. The lipophilicity profiles of the compounds were obtained from equilibrium dialysis and potentiometry, and compared with changes in NMR relaxation rates.

Results. The neutral form of hydroxyzine interacted mainly via hydrophobic interactions with the bilayer lipid core of the membrane, whereas for the cationic form both hydrophobic and electrostatic interactions were involved. Zwitterionic and anionic cetirizine were less lipophilic than its cation, which behaved like the corresponding species of hydroxyzine. Zwitterionic cetirizine interacted more by weak electrostatic interactions with the polar headgroups of phospholipids than by hydrophobic interactions with the membrane interior. The lipophilicity of its anion reflected the balance of repulsive electrostatic interactions between the carboxylate and phosphate groups and the hydrophobic interactions with the lipid core.

Conclusion. The study confirms that various mechanisms influence the interaction of solutes with liposomes. Combining experimental techniques and using suitable reference compounds proves useful.

cetirizine phosphatidylcholine liposomes equilibrium dialysis, potentiometry NMR distribution profiles lipophilicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    K. K. Pandya, R. A. Bangaru, T. P. Gandhi, I. A. Modi, R. I. Modi, and B. K. Chakravarthy. High–performance thin–layer chromatography for the determination of cetirizine in human plasma and its use in pharmacokinetic studies. J. Pharm. Pharmacol. 48:510–513 (1996).Google Scholar
  2. 2.
    A. Pagliara, B. Testa, P. A. Carrupt, P. Jolliet, C. Morin, D. Morin, S. Urien, J. P. Tillement, and J. P. Rihoux. Molecular structure and pharmacokinetic behavior of cetirizine, a zwitterionic antihistamine. J. Med. Chem. 41:853–863 (1998).Google Scholar
  3. 3.
    G. Ermondi, G. Caron, G. Bouchard, G. Plemper van Balen, A. Pagliara, T. Grandi, P. A. Carrupt, R. Fruttero, and B. Testa. Molecular dynamics and NMR exploration of the property space of the zwitterionic antihistamine cetirizine. Helv. Chim. Acta (in press).Google Scholar
  4. 4.
    G. V. Betageri and J. A. Rogers. The liposome as a distribution model in QSAR studies. Int. J. Pharm. 46:95–102 (1988).Google Scholar
  5. 5.
    U. Hellwich and R. Schubert. Concentration–dependent binding of the chiral beta–blocker oxprenolol to isoelectric or negatively charged unilamellar vesicles. Biochem. Pharmacol. 49:511–517 (1995).Google Scholar
  6. 6.
    C. Ottiger and H. Wunderli–Allenspach. Ideal partition behaviour of acids and bases in a phosphatidylcholine liposome/buffer equilibrium dialysis system. Eur. J. Pharm. Sci. 5:223–231 (1997).Google Scholar
  7. 7.
    A. Avdeef, K. J. Box, J. E. A. Comer, C. Hibbert, and K. Y. Tam. pH–metric log P. 10. Determination of vesicle membrane–water partition coefficients of ionizable drugs. Pharm. Res. 15:209–215 (1998).Google Scholar
  8. 8.
    A. Pagliara, P. A. Carrupt, G. Caron, P. Gaillard, and B. Testa, Lipophilicity profiles of ampholytes. Chem. Rev. 97:3385–3400 (1997).Google Scholar
  9. 9.
    M. J. Hope, M. B. Bally, G. Webb, and P. R. Cullis. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812:55–65 (1985).Google Scholar
  10. 10.
    S. D. Krämer, A. Braun, C. Jakits–Deiser, and H. W. Underli–Allenspach. Towards the predictability of drug–lipid membrane interactions: The pH–dependent affinity of propranolol to phosphatidylinositol containing liposomes. Pharm. Res. 15:739–744 (1998).Google Scholar
  11. 11.
    L. D. Mayer, M. J. Hope, and P. R. Cullis. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta 858:161–168 (1986).Google Scholar
  12. 12.
    X. R. Qi, Y. Maitani, and T. Nagai. Effect of soybean–derived sterols on the in vitro stability and the blood circulation of liposomes in mice. Int. J. Pharm. 114:33–41 (1995).Google Scholar
  13. 13.
    X. R. Qi, Y. Maitani, and T. Nagai. Rates of systemic degradation and reticuloendothelial system uptake of calcein in the dipalmitoylphosphatidylcholine liposomes with soybean–derived sterols in mice. Pharm. Res. 12:49–52 (1995).Google Scholar
  14. 14.
    K. Muramatsu, Y. Maitani, Y. Machida, and T. Nagai. Effect of soybean–derived sterol and its glucoside mixtures on the stability of dipamitoylphosphatidylcholine and dipalmitoylphosphatidylcholine/cholesterol liposomes. Int. J. Pharm. 107:1–8 (1994).Google Scholar
  15. 15.
    F. Frézard, C. Santaella, P. Vierling, and J. G. Riess. Permeability and stability in buffer and in human serum of fluorinated phospholipid–based liposomes. Biochim. Biophys. Acta 1192:61–70 (1994).Google Scholar
  16. 16.
    M. Takayama, S. Itoh, T. Nagasaki, and I. Tanimizu, A new enzymatic method for determination of serum choline–containing phospholipids. Clin. Chim. Acta 79:93–98 (1977).Google Scholar
  17. 17.
    P. Trinder. Determination of glucose in blood using glucose oxidase with an alernative oxygen acceptor. Ann. Clin. Biochem. 6:24–27 (1969).Google Scholar
  18. 18.
    S. D. Krämer, C. Jakits–Deiser, and H. Wunderli–Allenspach. Free fatty acids cause pH–dependent changes in drug–lipid membrane interactions around physiological pH. Pharm. Res. 14:827–832 (1997).Google Scholar
  19. 19.
    G. Caron, F. Reymond, P. A. Carrupt, H. H. Girault, and B. Testa. Combined molecular lipophilicity descriptors and their role in understanding intramolecular effects. Pharm. Sci. Technolog. Today 2:327–335 (1999).Google Scholar
  20. 20.
    A. Avdeef. pH–Metric log P. Part 1. Difference plots for determining ion–pair octanol–water partition coefficients of multiprotic substances. Quant. Struct.–Act. Relat. 11:510–517 (1992).Google Scholar
  21. 21.
    G. Caron, P. Gaillard, P. A. Carrupt, and B. Testa. Lipophilicity behavior of model and medicinal compounds containing a sulfide, sulfoxide, or sulfone moiety. Helv. Chim. Acta 80:449–462 (1997).Google Scholar
  22. 22.
    A. Avdeef. pH–Metric log P. II. Refinement of partition coefficients and ionization constants of multiprotic substances. J. Pharm. Sci. 82:183–190 (1993).Google Scholar
  23. 23.
    R. Fruttero, G. Caron, E. Fornatto, D. Boschi, G. Ermondi, A. Gasco, P. A. Carrupt, and B. Testa. Mechanisms of liposomes/water partitioning of (p–methylbenzyl)alkylamines. Pharm. Res. 15:1407–1413 (1998).Google Scholar
  24. 24.
    A. Kantar, J. P. Rihoux, and R. Fiorini. Effect of cetirizine on plasma membrane of human eosinophils, neutrophils and platelets: a dose response study. Eur. J. Pharm. Sci. 4:101–107 (1996).Google Scholar
  25. 25.
    F. E. R. Simons and K. J. Simons. Pharmacokinetic optimization of histamine H1–receptor antagonist therapy. Clin. Pharmacokin. 21:372–393 (1991).Google Scholar
  26. 26.
    J. P. Tillement and E. Albengres. Peut–on adapter la distribution d'un médicament dans l'organisme aux localisations de ses cibles? L'exemple d'antihistaminiques (anti H1) et de la cétirizine. Allergie et Immunologie 28:330–332 (1996).Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Georgette Plemper van Balen
    • 1
  • Giulia Caron
    • 1
    • 2
  • Giuseppe Ermondi
    • 3
  • Alessandra Pagliara
    • 1
  • Teresa Grandi
    • 1
  • Géraldine Bouchard
    • 1
  • Roberta Fruttero
    • 4
  • Pierre–Alain Carrupt
    • 1
  • Bernard Testa
    • 1
  1. 1.Institut de Chimie Thérapeutique, Section de PharmacieUniversité de LausanneLausanneSwitzerland
  2. 2.Dipartimento di Scienza e Tecnologia del FarmacoUniversità di TorinoTorinoItaly
  3. 3.DISCAFF, Università del Piemonte OrientaleNovara
  4. 4.Dipartimento di Scienza e Tecnologia del FarmacoUniversità di TorinoTorinoItaly

Personalised recommendations